Shares of Alembic Pharmaceuticals rose 1 percent in the early trade on Tuesday as its associate company Rhizen Pharmaceuticals received USFDA approval for cancer drug.
“Rhizen Pharmaceuticals SA announced that USFDA has granted orphan-drug designation for the active moiety of Tenalisib, the company’s highly selective and orally active dual PI3K delta/gamma inhibitor, for the treatment of peripheral T-cell lymphoma,” as per BSE release.
Orphan-drug designation is granted to a drug or biological product intended to treat a rare disease in the United States.
“Rhizen Pharmaceuticals SA announced that USFDA has granted orphan-drug designation for the active moiety of Tenalisib, the company’s highly selective and orally active dual PI3K delta/gamma inhibitor, for the treatment of peripheral T-cell lymphoma,” as per BSE release.
Orphan-drug designation is granted to a drug or biological product intended to treat a rare disease in the United States.
No comments:
Post a Comment